Clinical trials: Anginal Pain
Major Cardiovascular Event, Established Atherosclerotic Cardiovascular Disease
A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease
The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI)…
- Trial name
- NCT06295679
- Where
- 90 sites in China
- Volunteers
- 7,000 people
- Sponsor
- Amgen
Coronary Artery Disease, Myocardial Ischemia
Feasibility Study of the Amaranth Medical FORTITUDE Bioresorbable Drug-Eluting Coronary Stent
The purpose of this study is to evaluate the safety and feasibility of a new coronary artery stent for treating blockages in the arteries supplying blood to the heart muscle.
- Trial name
- MEND II (NCT02189499)
- Testing
- AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold
- Where
- 4 sites in Colombia
- Volunteers
- 42 people
- Sponsor
- Amaranth Medical Inc.
Cardiovascular Diseases
A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin
AMR101 (icosapent ethyl [ethyl-EPA]) is a highly purified ethyl ester of eicosapentaenoic acid (EPA) developed by Amarin Pharma Inc.
- Trial name
- REDUCE-IT (NCT01492361)
- Testing
- AMR101, Statin therapy
- Where
- 410 sites in United States, Australia and 9 more
- Volunteers
- 8,179 people
- Sponsor
- Amarin Pharma Inc.
Hypertension, Hypercholesterolemia
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
The primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension…
- Conditions
- Hypertension, Hypercholesterolemia, Angina Pectoris
- Trial name
- NCT01190007
- Testing
- Caduet
- Where
- 20 sites in Japan
- Volunteers
- 159 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Coronary Artery Stenoses, Stable Angina
e-BioMatrix 6 Month DAPT France
Prospective, multi-center observational study to be conducted in up to 30 French interventional cardiology centers. The purpose of this observational study is to capture, in French Centers, clinical data of the BioMatrix Flex™…
- Conditions
- Coronary Artery Stenoses, Stable Angina, Ischemia, NSTEMI - Non-ST Segment Elevation MI
- Trial name
- NCT03461484
- Volunteers
- 2,098 people
- Sponsor
- Biosensors Europe SA
Angina
A TSHRN1201 Sub-study-To Evaluate the Effects of add-on Ranolazine on Exercise Tolerance and Angina Frequency
This is a double-blind, randomized, placebo-controlled, and parallel study. The study is comprised of three main phases: a single-blind placebo run-in qualifying phase lasting about 14 days, a double-blind treatment phase of 12…
- Trial name
- NCT03401502
- Testing
- Ranolazine
- Where
- Taiwan
- Volunteers
- 20 people
- Sponsor
- TSH Biopharm Corporation Limited
Acute Coronary Syndrome
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects
This study will evaluate the relative efficacy and safety of prasugrel and clopidogrel in a medically managed Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) acute coronary syndrome (ACS) population (that is…
- Trial name
- TRILOGY ACS (NCT00699998)
- Testing
- Clopidogrel, Prasugrel, Commercially-available Aspirin
- Where
- 688 sites in United States, Argentina and 51 more
- Volunteers
- 9,326 people
- Sponsor
- Eli Lilly and Company
Refractory Angina Pectoris
Extracorporeal Shockwave Therapy for the Treatment of Chronic Angina Pectoris
Low intensity shockwaves have been proven in animal studies to induce local growth of new blood vessels from existing ones. The hypothesis of this study is that shockwave therapy could improve the symptoms of patients with…
- Trial name
- NCT01567592
- Testing
- Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- Medispec
Angina, Unstable, Angioplasty, Transluminal, Percutaneous Coronary
A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
The purpose of this study is to evaluate the effectiveness and safety of abciximab (an anti-platelet therapy) versus placebo in patients undergoing high risk coronary angioplasty.
- Trial name
- NCT00269893
- Testing
- Abciximab
- Volunteers
- 2,038 people
- Sponsor
- Centocor, Inc.
Ischemic Heart Disease, Angina Pectoris
Absorb GT1 Japan PMS
The purpose of the Surveillance is to know the frequency and status of adverse device effects and adverse events in order to assure the safety of the new medical device, and to collect efficacy and safety information for…
- Conditions
- Ischemic Heart Disease, Angina Pectoris, Coronary Artery Disease, Coronary Artery Occlusion
- Trial name
- NCT03409731
- Testing
- ABSORB GT1 BVS
- Where
- 15 sites in Japan
- Volunteers
- 135 people
- Sponsor
- Abbott Medical Devices
Stable Angina
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
- Trial name
- NCT02575833
- Testing
- Erenumab
- Where
- 33 sites in United States, Bulgaria and 8 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III All-comers Orsiro Safety and Performance Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-III (NCT01553526)
- Where
- 43 sites in Austria, Chile and 11 more
- Volunteers
- 1,356 people
- Sponsor
- Biotronik AG
Vasospastic Angina
A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
This study will be conducted in accordance with the local regulation of New Drug Application. Overall duration of this trial will be 3 years after approval of KFDA.
- Trial name
- STELLA (NCT02087007)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Stable Angina, Acute Coronary Syndrome
Novasight Hybrid Intravascular Ultrasound and Optical Coherence Tomography System (IVUS OCT)
Collection of coronary images with a hybrid IVUS OCT system.
- Trial name
- NCT03484975
- Testing
- Observation group
- Where
- Canada
- Volunteers
- 23 people
- Sponsor
- Conavi
Chronic Myocardial Ischemia, Refractory Angina Pectoris
Efficacy and Safety of Targeted Intramyocardial Delivery of Auto CD34+ Stem Cells for Improving Exercise Capacity in Subjects With Refractory Angina
The purpose of the study is to assess the safety and efficacy of targeted intramyocardial delivery of Auto-CD34+ cells for increasing exercise time and amelioration of anginal symptoms in subjects with refractory angina and…
- Conditions
- Chronic Myocardial Ischemia, Refractory Angina Pectoris, Advanced Coronary Heart Disease
- Trial name
- RENEW (NCT01508910)
- Testing
- Auto-CD34+ cells, Standard of care
- Where
- 41 sites in United States
- Volunteers
- 291 people
- Sponsor
- Lisata Therapeutics, Inc.
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Stable Angina, Unstable Angina
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or…
- Conditions
- Stable Angina, Unstable Angina, ACS - Acute Coronary Syndrome, STEMI
- Trial name
- eCOBRA (NCT03103620)
- Testing
- COBRA PzF Coronary Stent System
- Where
- 18 sites in France
- Volunteers
- 1,027 people
- Sponsor
- CeloNova BioSciences, Inc.
Acute Coronary Syndrome
FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes
The objective of this study is to evaluate the safety and efficacy of A 002 when added to high dose atorvastatin in subjects with an acute coronary syndrome (ACS)
- Trial name
- FRANCIS-ACS (NCT00743925)
- Testing
- Varespladib Methyl (A-002)
- Where
- 44 sites in Georgia, Russia and 1 more
- Volunteers
- 625 people
- Sponsor
- Anthera Pharmaceuticals
Stable Coronary Artery Disease (CAD), Unstable Angina (Troponin Negative)
Safety of Argatroban Infusion in Conduction Disturbances
To determine change of QTc interval during intravenous argatroban infusion in patients undergoing percutaneous coronary intervention (PCI)
- Trial name
- SAICoDis (NCT05740371)
- Testing
- Argatroban
- Where
- 2 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Tanabe Pharma GmbH
Ischemic Heart Disease, Stable Coronary Artery Disease
To Evaluate Safety and Efficacy of CGBIO Stent Compared to Biomatrix Flex Stent
to evaluate safety and efficacy of CGBIO stent(DES) compared to Biomatrix flex stent(DES)
- Conditions
- Ischemic Heart Disease, Stable Coronary Artery Disease, Stable Angina, Unstable Angina
- Trial name
- NCT03089450
- Testing
- CGBio stent, Biomatrix flex
- Where
- South Korea
- Volunteers
- 112 people
- Sponsor
- CGBio Inc.